Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06203977
PHASE1
Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR)
Sponsor: Hamilton Health Sciences Corporation
View on ClinicalTrials.gov
Summary
Phase 1 basket trial including 2 open-label single-arm cohorts: REPAIR CKD cohort and REPAIR Dialysis cohort. Open label colchicine 0.3 mg daily for 8 weeks followed, in patients who tolerated the 0.3 mg dose, by forced titration to 0.6 mg daily for 8 weeks.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2024-11-15
Completion Date
2026-05-31
Last Updated
2025-03-12
Healthy Volunteers
No
Conditions
Interventions
DRUG
Colchicine
0.3mg and 0.6mg tablets
Locations (3)
University of Alberta Hospital
Edmonton, Alberta, Canada
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada